

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
29 March 2001 (29.03.2001)

PCT

(10) International Publication Number
WO 01/21600 A1(51) International Patent Classification⁷: C07D 261/04,
A61K 31/41

(21) International Application Number: PCT/KR00/01047

(22) International Filing Date:
18 September 2000 (18.09.2000)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
PCT/KR99/00561
17 September 1999 (17.09.1999) KR
1999/48608 4 November 1999 (04.11.1999) KR(71) Applicant (for all designated States except US): LG
CHEMICAL LTD. [KR/KR]; 20, Yoido-dong, Yong-
dungpo-ku, Seoul 150-010 (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KIM, Eunice,
Eun-Kyeong [KR/KR]; LG Apt. 8-506, 381-42, Do-
ryong-dong, Yuseong-ku, Daejeon 305-340 (KR).
PARK, Mi-Jeong [KR/KR]; Expo Apt., 305-402,
Jeonmin-dong, Yuseong-ku, Daejeon 305-390 (KR).
LEE, Tae-Hee [KR/KR]; LG Apt. 7-505, 381-42,
Doryong-dong, Yuseong-ku, Daejeon 305-340 (KR).
CHANG, Hye-Kyung [KR/KR]; LG Apt. 8-204, 381-42,
Doryong-dong, Yuseong-ku, Daejeon 305-340 (KR).
PARK, Tae-Kyo [KR/KR]; LG Apt. 8-302, 381-42,Doryong-dong, Yuseong-ku, Daejeon 305-340 (KR).
KANG, Chang-Yuil [KR/KR]; College of Pharmacy,
Seoul National University, Shillim-dong, Kwanak-ku,
Seoul 151-742 (KR). KIM, Young-Myeong [KR/KR];
Dept. of Molecular and Cellular Biochemistry, Kangwon
National University, Kangwon-do, Chuncheon 200-701
(KR). MOON, Kwang-Yul [KR/KR]; Sammeri Apt.,
102-304, Doosan-dong, Seo-ku, Daejeon 302-780 (KR).
OH, Young-Leem [KR/KR]; Hyundai Apt., 104-802,
Sunhwa-dong, Joong-ku, Daejeon 301-050 (KR). MIN,
Chang-Hee [KR/KR]; Doongji Apt., 109-1404, Doon-
san-dong, Seo-ku, Daejeon 302-120 (KR). CHUNG,
Hyun-Ho [KR/KR]; LG Apt. 9-205, 381-42, Dory-
ong-dong, Yuseong-ku, Daejeon 305-340 (KR).(74) Agent: CHOI, Kyn-Pal; 824-11, Yeoksam-dong, Kang-
nam-ku, Seoul 135-080 (KR).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: CASPASE INHIBITOR



(57) Abstract: The present invention relates to an isoxazoline derivative of formula (I), the pharmaceutically acceptable salts, esters and stereochemically isomeric forms thereof, and the use of the derivative in inhibiting the activity of caspases. The present invention also relates to a pharmaceutical composition for preventing inflammation and apoptosis which comprises the isoxazoline derivative, pharmaceutically acceptable salts, esters and stereochemically isomeric forms thereof and the process for preparing the same. The derivative according to the present invention can be effectively used in treating diseases due to caspases, such as, for example the disease in which cells are abnormally died, dementia, cerebral stroke, AIDS, diabetes, gastric ulcer, hepatic injury by hepatitis, sepsis, organ transplantation rejection reaction and anti-inflammation.

WO 01/21600 A1